Sage Therapeutics' (SAGE) CORAL Phase 3 Study Likely to Meet Primary Endpoint, But Not Enough to Drive Stock Higher - Needham & Company
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Buy rating and $85.00 price target on Sage Therapeutics (NASDAQ: SAGE)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
